Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

HFCAS OpenIR

	Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study
	Fang, Y.1; Pan, H.1; Shou, J.2; Hong, W.3; Yang, X.4 ; Zhu, D.5; Zhou, Y.6 ; Lan, F.7; Rao, C.8; Chen, J.9
	2021-03-01
发表期刊	JOURNAL OF THORACIC ONCOLOGY
ISSN	1556-0864
关键词	Anlotinib NSCLC anti-angiogenesis
收录类别	SCI
语种	英语
WOS研究方向	Oncology ; Respiratory System
WOS类目	Oncology ; Respiratory System
WOS记录号	WOS:000631349602067
出版者	ELSEVIER SCIENCE INC
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/121730
专题	中国科学院合肥物质科学研究院
作者单位	1.Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China 2.Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 4.First Hosp Jiaxing, Jiaxing, Peoples R China 5.Jinhua Municipal Cent Hosp, Jinhua, Zhejiang, Peoples R China 6.Cent Hosp Lishui City, Lishui, Peoples R China 7.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China 8.Univ Chinese Acad Sci, Hwa Mei Hosp, Ningbo, Peoples R China 9.Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China
推荐引用方式 GB/T 7714	Fang, Y.,Pan, H.,Shou, J.,et al. Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study[J]. JOURNAL OF THORACIC ONCOLOGY,2021,16.
APA	Fang, Y..,Pan, H..,Shou, J..,Hong, W..,Yang, X..,...&Chen, J..(2021).Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study.JOURNAL OF THORACIC ONCOLOGY,16.
MLA	Fang, Y.,et al."Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study".JOURNAL OF THORACIC ONCOLOGY 16(2021).